Published in J Alzheimers Dis on November 01, 2000
CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology (2008) 2.43
Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx (2004) 2.02
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 1.07
Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol (2004) 1.01
Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Biochim Biophys Acta (2008) 1.01
Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? Biochem J (2012) 0.97
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci (2013) 0.94
Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol (2013) 0.93
Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res (2010) 0.92
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS One (2013) 0.92
Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med (2009) 0.92
Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis (2014) 0.89
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
Cortical thickness estimation in longitudinal stroke studies: A comparison of 3 measurement methods. Neuroimage Clin (2014) 0.87
No neurochemical evidence for brain injury caused by heading in soccer. Br J Sports Med (2007) 0.85
Vulnerabilities in the tau network and the role of ultrasensitive points in tau pathophysiology. PLoS Comput Biol (2010) 0.82
Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Res Ther (2004) 0.82
Biological markers and Alzheimer disease: a canadian perspective. Int J Alzheimers Dis (2010) 0.82
Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. World J Psychiatry (2011) 0.81
Cerebrospinal fluid markers before and after shunting in patients with secondary and idiopathic normal pressure hydrocephalus. Cerebrospinal Fluid Res (2008) 0.81
CSF phospho-tau is independent of age, cognitive status and gender of neurological patients. J Neurol (2009) 0.80
The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. Psychiatr Clin North Am (2015) 0.76
Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults. Front Aging Neurosci (2017) 0.75
BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. J Alzheimers Dis (2017) 0.75
Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside. Diagnostics (Basel) (2017) 0.75
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 7.43
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol (1995) 3.23
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett (1995) 3.15
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care (2000) 2.97
Active Immunization against Diphtheria by the Combined Subcutaneous and Intranasal Method: (Section of Epidemiology and Stare Medicine). Proc R Soc Med (1937) 2.87
Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A (1999) 2.82
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Normal pressure hydrocephalus: vascular white matter changes on MR images must not exclude patients from shunt surgery. AJNR Am J Neuroradiol (2001) 2.46
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res (2001) 2.19
Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem (1993) 2.18
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol (2005) 2.04
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology (2003) 1.85
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J (1994) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Specific Neisseria gonorrhoeae DNA-probes derived from ribosomal RNA. J Gen Microbiol (1989) 1.82
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72
Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther (2006) 1.70
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Autonomic and thermal sensory symptoms and dysfunction after stroke. Stroke (1995) 1.62
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta Paediatr (2001) 1.60
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry (2003) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke (1995) 1.58
Behavioral aftereffects of reinforcement and its omission as a function of reinforcement magnitude. J Exp Anal Behav (1973) 1.57
New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol (2002) 1.51
Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol (1997) 1.51
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
Brain specific proteins in posthaemorrhagic ventricular dilatation. Arch Dis Child Fetal Neonatal Ed (2001) 1.46
The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. J Cell Biol (2001) 1.46
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
The correlation between the radiological examination and the irrigation findings in maxillary sinusitis. Acta Otolaryngol (1970) 1.42
Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol (2000) 1.42
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease. Am J Pathol (1994) 1.28
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26